Date Printed: 03/13/2008 Date Updated: 02/04/2006 Version 1.9

Transcription

1 SIGMA-ALDRICH MATERIAL SAFETY DATA SHEET Date Printed: 03/13/2008 Date Updated: 02/04/2006 Version 1.9 Section 1 - Product and Company Information Product Name CADMIUM CHLORIDE ANHYDROUS Product Number Brand FLUKA Company Address Technical Phone: Fax: Emergency Phone: Sigma-Aldrich Canada, Ltd 2149 Winston Park Drive Oakville ON L6H 6J8 CA Section 2 - Composition/Information on Ingredient Substance Name CAS # SARA 313 CADMIUM CHLORIDE Yes Formula CdCl2 Synonyms Caddy * Cadmium dichloride * Dichlorocadmium * Kadmiumchlorid (German) * VI-Cad RTECS Number: EV Section 3 - Hazards Identification EMERGENCY OVERVIEW Highly Toxic (USA) Very Toxic (EU). Dangerous for the environment. May cause cancer. May cause heritable genetic damage. May impair fertility. May cause harm to the unborn child. Also toxic if swallowed. Also very toxic by inhalation. Toxic: danger of serious damage to health by prolonged exposure through inhalation and if swallowed. Very toxic to aquatic organisms, may cause long-term adverse effects in the aquatic environment. Danger: Contains cadmium. Cancer hazard. Avoid creating dust. Can cause lung and kidney disease. Calif. Prop. 65 carcinogen & developmental hazard. HMIS RATING HEALTH: 3* FLAMMABILITY: 0 REACTIVITY: 1 NFPA RATING HEALTH: 3 FLAMMABILITY: 0 REACTIVITY: 1 *additional chronic hazards present. For additional information on toxicity, please refer to Section 11. Section 4 - First Aid Measures

2 ORAL EXPOSURE If swallowed, wash out mouth with water provided person is conscious. Call a physician immediately. INHALATION EXPOSURE If inhaled, remove to fresh air. If not breathing give artificial respiration. If breathing is difficult, give oxygen. DERMAL EXPOSURE In case of skin contact, flush with copious amounts of water for at least 15 minutes. Remove contaminated clothing and shoes. Call a physician. EYE EXPOSURE In case of contact with eyes, flush with copious amounts of water for at least 15 minutes. Assure adequate flushing by separating the eyelids with fingers. Call a physician. Section 5 - Fire Fighting Measures FLASH POINT AUTOIGNITION TEMP FLAMMABILITY EXTINGUISHING MEDIA Suitable: Water spray. Carbon dioxide, dry chemical powder, or appropriate foam. FIREFIGHTING Protective Equipment: Wear self-contained breathing apparatus and protective clothing to prevent contact with skin and eyes. Specific Hazard(s): Emits toxic fumes under fire conditions. Section 6 - Accidental Release Measures PROCEDURE TO BE FOLLOWED IN CASE OF LEAK OR SPILL Evacuate area. PROCEDURE(S) OF PERSONAL PRECAUTION(S) Wear self-contained breathing apparatus, rubber boots, and heavy rubber gloves. METHODS FOR CLEANING UP Sweep up, place in a bag and hold for waste disposal. Avoid raising dust. Ventilate area and wash spill site after material pickup is complete. Section 7 - Handling and Storage HANDLING User Exposure: Do not breathe dust. Do not get in eyes, on skin, on clothing. Avoid prolonged or repeated exposure. STORAGE Suitable: Keep tightly closed. Handle and store under nitrogen. SPECIAL REQUIREMENTS FLUKA Page 2

3 Air and moisture sensitive. Handle under inert gas. Section 8 - Exposure Controls / PPE ENGINEERING CONTROLS Safety shower and eye bath. Use only in a chemical fume hood. PERSONAL PROTECTIVE EQUIPMENT Respiratory: Use respirators and components tested and approved under appropriate government standards such as NIOSH (US) or CEN (EU). Where risk assessment shows air-purifying respirators are appropriate use a full-face particle respirator type N100 (US) or type P3 (EN 143) respirator cartridges as a backup to engineering controls. If the respirator is the sole means of protection, use a full-face supplied air respirator. Hand: Compatible chemical-resistant gloves. Eye: Chemical safety goggles. GENERAL HYGIENE MEASURES Wash contaminated clothing before reuse. Wash thoroughly after handling. EXPOSURE LIMITS, RTECS Country Source Type Value USA ACGIH TWA 0.01 MG(CD)/M3 Remarks: inhalable dust USA ACGIH TWA MG(CD)/M3 Remarks: respirable dust USA MSHA Standard-air TWA 0.2 MG(CD)/M3 New Zealand OEL Remarks: check ACGIH TLV USA NIOSH LOWEST FEASIBLE CONC. Section 9 - Physical/Chemical Properties Appearance Physical State: Solid Color: White Property Value At Temperature or Pressure Molecular Weight AMU ph BP/BP Range 960 C MP/MP Range 568 C Freezing Point Vapor Pressure 10 mmhg 656 C Vapor Density 6.3 g/l Saturated Vapor Conc. SG/Density 4.05 g/cm3 Bulk Density Odor Threshold Volatile% VOC Content Water Content Solvent Content Evaporation Rate Viscosity Surface Tension Partition Coefficient Decomposition Temp. Flash Point Explosion Limits FLUKA Page 3

4 Flammability Autoignition Temp Refractive Index Optical Rotation Miscellaneous Data Solubility = not available Section 10 - Stability and Reactivity STABILITY Stable: Stable. Conditions to Avoid: Moisture. Air. Materials to Avoid: Oxidizing agents, Bromine trifluoride. HAZARDOUS DECOMPOSITION PRODUCTS Hazardous Decomposition Products: Nature of decomposition products not known. HAZARDOUS POLYMERIZATION Hazardous Polymerization: Will not occur Section 11 - Toxicological Information ROUTE OF EXPOSURE Skin Contact: May cause skin irritation. Skin Absorption: May be harmful if absorbed through the skin. Eye Contact: May cause eye irritation. Inhalation: May be fatal if inhaled. Material may be irritating to mucous membranes and upper respiratory tract. Ingestion: Toxic if swallowed. TARGET ORGAN(S) OR SYSTEM(S) Kidneys. Lungs. Pancreas. Male reproductive system. Liver. Bones. SIGNS AND SYMPTOMS OF EXPOSURE Acute inhalation exposure to cadmium fumes may cause "metal fume fever" with flu-like symptoms of weakness, fever, headache, chills, nausea, vomiting, dizziness, sweating, muscular pain, cough and difficulty breathing. Acute pulmonary edema may develop within 24 hours and reaches a maximum by three days.the first chronic effect of exposure to cadmium is generally kidney damage, manifested by excretion of excessive protein in the urine, followed by anemia, teeth discoloration and loss of smell. Cadmium also is believed to cause pulmonary emphysema and bone disease. TOXICITY DATA Oral Woman 3000 mg/kg LDLO Remarks: Gastrointestinal:Hypermotility, diarrhea. Lungs, Thorax, or Respiration:Acute pulmonary edema. Vascular:BP lowering not charactertized in autonomic section. Oral Rat 88 mg/kg FLUKA Page 4

5 Remarks: Gastrointestinal:Changes in structure or function of salivary glands. Gastrointestinal:Hypermotility, diarrhea. Gastrointestinal:Nausea or vomiting. Intraperitoneal Rat 1800 UG/KG Subcutaneous Rat UG/KG Intravenous Rat 5463 UG/KG Intramuscular Rat 25 MG/KG Oral Mouse 60 mg/kg Remarks: Nutritional and Gross Metabolic:Weight loss or decreased weight gain. Intraperitoneal Mouse 9300 UG/KG Remarks: Blood: Hemorrhage. Subcutaneous Mouse 3200 UG/KG Remarks: Nutritional and Gross Metabolic:Weight loss or decreased weight gain. Intravenous Mouse 3500 UG/KG Intravenous Rabbit 2500 UG/KG Oral Guinea pig 63 mg/kg Oral Chicken 165 mg/kg FLUKA Page 5

6 Intramuscular Frog 10 MG/KG Remarks: Biochemical:Enzyme inhibition, induction, or change in blood or tissue levels: Other transferases. Biochemical:Enzyme inhibition, induction, or change in blood or tissue levels: Phosphatases. Biochemical:Enzyme inhibition, induction, or change in blood or tissue levels: Dehydrogenases. CHRONIC EXPOSURE - CARCINOGEN Result: Chronic exposure to cadmium may cause lung and prostate cancer. This is or contains a component that has been reported to be carcinogenic based on its IARC, OSHA, ACGIH, NTP, or EPA classification. Route of Application: Inhalation Dose: 20 UG/M3 Exposure Time: 23H/78W- Frequency: C Result: Tumorigenic:Carcinogenic by RTECS criteria. Lungs, Thorax, or Respiration:Tumors. Dose: 3666 UG/KG Result: Tumorigenic:Carcinogenic by RTECS criteria. Tumorigenic Effects: Testicular tumors. Tumorigenic:Tumors at site or application. Route of Application: Intramuscular Dose: 4500 UG/KG Result: Tumorigenic:Facilitates action of known carcinogens. Tumorigenic:Equivocal tumorigenic agent by RTECS criteria. Route of Application: Parenteral Dose: 1700 UG/KG Result: Tumorigenic:Facilitates action of known carcinogens. Tumorigenic:Equivocal tumorigenic agent by RTECS criteria. Route of Application: Parenteral Dose: 6163 UG/KG Result: Endocrine:Tumors. Tumorigenic:Equivocal tumorigenic agent by RTECS criteria. Dose: 5499 UG/KG Result: Tumorigenic:Equivocal tumorigenic agent by RTECS criteria. Tumorigenic Effects: Testicular tumors. Dose: 4500 UG/KG Result: Tumorigenic:Tumors at site or application. Tumorigenic:Equivocal tumorigenic agent by RTECS criteria. FLUKA Page 6

7 Route of Application: Inhalation Dose: 41 UG/M3 Exposure Time: 23H/78W- Frequency: C Result: Lungs, Thorax, or Respiration:Tumors. Tumorigenic:Carcinogenic by RTECS criteria. Route of Application: Inhalation Dose: 82 UG/M3 Exposure Time: 23H/78W- Frequency: C Result: Lungs, Thorax, or Respiration:Tumors. Tumorigenic:Carcinogenic by RTECS criteria. Dose: 7332 UG/KG Result: Tumorigenic:Tumors at site or application. Tumorigenic:Carcinogenic by RTECS criteria. Tumorigenic Effects: Testicular tumors. Dose: 5499 UG/KG Result: Tumorigenic:Tumors at site or application. Tumorigenic Effects: Testicular tumors. Tumorigenic:Neoplastic by RTECS criteria. Dose: 3666 MG/KG Result: Tumorigenic Effects: Testicular tumors. Tumorigenic:Carcinogenic by RTECS criteria. Gastrointestinal:Tumors. Dose: 7332 MG/KG Result: Tumorigenic:Carcinogenic by RTECS criteria. Gastrointestinal:Tumors. Tumorigenic Effects: Testicular tumors. Dose: NG/KG Exposure Time: 2D Frequency: I Result: Tumorigenic:Tumors at site or application. Tumorigenic:Carcinogenic by RTECS criteria. Dose: 9 MG/KG Result: Tumorigenic:Tumors at site or application. Tumorigenic:Carcinogenic by RTECS criteria. Tumorigenic Effects: Testicular tumors. OSHA CARCINOGEN LIST Rating: cancer hazard FLUKA Page 7

8 IARC CARCINOGEN LIST Rating: Group 1 Group 1 Rating: Group 1 NTP CARCINOGEN LIST Rating: Known to be carcinogenic. ACGIH CARCINOGEN LIST Rating: A2 Rating: A2 IRIS/EPA CARCINOGEN LIST Rating: Group B2 CHRONIC EXPOSURE - TERATOGEN Result: May cause congenital malformation in the fetus. Dose: UG/KG Exposure Time: (6-14D PREG) Result: Specific Developmental Abnormalities: Urogenital system. Effects on Embryo or Fetus: Fetal death. Dose: 17 MG/KG Exposure Time: (6W MALE/6W PRE-20D PREG) Result: Specific Developmental Abnormalities: Musculoskeletal system. Dose: 280 MG/KG Exposure Time: (6-19D PREG) Result: Specific Developmental Abnormalities: Cardiovascular (circulatory) system. Dose: 200 UG/M3/24H Route of Application: Inhalation Exposure Time: (1-21D PREG) Result: Effects on Embryo or Fetus: Other effects to embryo. Maternal Effects: Other effects. Nutritional and Gross Metabolic:Weight loss or decreased weight gain. Dose: 600 UG/M3/24H Route of Application: Inhalation Exposure Time: (1-21D PREG) Result: Effects on Embryo or Fetus: Fetotoxicity (except death, e.g., stunted fetus). Dose: 130 UG/M3 Route of Application: Inhalation Exposure Time: (1-19D PREG) Result: Effects on Embryo or Fetus: Fetotoxicity (except death, e.g., stunted fetus). Effects on Embryo or Fetus: Fetal death. FLUKA Page 8

9 Dose: 2933 UG/KG Route of Application: Intraperitoneal Exposure Time: (10D PREG) Result: Specific Developmental Abnormalities: Body wall. Specific Developmental Abnormalities: Musculoskeletal system. Specific Developmental Abnormalities: Gastrointestinal system. Dose: 2933 UG/KG Route of Application: Intraperitoneal Exposure Time: (10D PREG) Result: Specific Developmental Abnormalities: Urogenital system. Effects on Embryo or Fetus: Extra embryonic structures (e.g., placenta, umbilical cord). Dose: 2 MG/KG Route of Application: Intraperitoneal Exposure Time: (10D PREG) Result: Specific Developmental Abnormalities: Central nervous system. Specific Developmental Abnormalities: Musculoskeletal system. Specific Developmental Abnormalities: Urogenital system. Dose: 7 MG/KG Exposure Time: (12D PREG) Result: Effects on Embryo or Fetus: Maternal-fetal exchange. Dose: 4892 UG/KG Exposure Time: (19D PREG) Result: Effects on Embryo or Fetus: Extra embryonic structures (e.g., placenta, umbilical cord). Effects on Embryo or Fetus: Fetotoxicity (except death, e.g., stunted fetus). Effects on Embryo or Fetus: Fetal death. Dose: 32 MG/KG Exposure Time: (12-15D PREG) Result: Specific Developmental Abnormalities: Respiratory system. Dose: 4500 UG/KG Route of Application: Intravenous Exposure Time: (10D PREG) Result: Effects on Embryo or Fetus: Fetotoxicity (except death, e.g., stunted fetus). Specific Developmental Abnormalities: Eye, ear. Specific Developmental Abnormalities: Central nervous system. Dose: 2 MG/KG Route of Application: Intravenous Exposure Time: (12D PREG) Result: Specific Developmental Abnormalities: Central nervous system. Specific Developmental Abnormalities: Musculoskeletal system. Specific Developmental Abnormalities: Urogenital system. FLUKA Page 9

10 Dose: 6197 UG/KG Exposure Time: (1-19D PREG) Result: Effects on Embryo or Fetus: Fetotoxicity (except death, e.g., stunted fetus). Effects on Newborn: Other postnatal measures or effects. Dose: 248 GM/KG Exposure Time: (1-19D PREG) Result: Specific Developmental Abnormalities: Blood and lymphatic system (including spleen and marrow). Effects on Embryo or Fetus: Fetotoxicity (except death, e.g., stunted fetus). Dose: 6 MG/KG Exposure Time: (15-19D PREG) Result: Effects on Newborn: Delayed effects. Specific Developmental Abnormalities: Endocrine system. Effects on Newborn: Growth statistics (e.g., reduced weight gain). Dose: 33 MG/KG Exposure Time: (7-9D PREG) Result: Effects on Embryo or Fetus: Fetotoxicity (except death, e.g., stunted fetus). Effects on Embryo or Fetus: Fetal death. Dose: 1833 UG/KG Route of Application: Intraperitoneal Exposure Time: (7D PREG) Result: Specific Developmental Abnormalities: Central nervous system. Specific Developmental Abnormalities: Eye, ear. Specific Developmental Abnormalities: Craniofacial (including nose and tongue). Dose: 3666 UG/KG Exposure Time: (13D PREG) Result: Effects on Embryo or Fetus: Fetal death. Dose: 2500 UG/KG Exposure Time: (7D PREG) Result: Specific Developmental Abnormalities: Central nervous system. Specific Developmental Abnormalities: Eye, ear. Specific Developmental Abnormalities: Musculoskeletal system. Dose: UG/KG Route of Application: Implant Exposure Time: (5-18D PREG) Result: Specific Developmental Abnormalities: Other developmental abnormalities. Specific Developmental FLUKA Page 10

11 Abnormalities: Musculoskeletal system. Species: Rabbit Dose: 815 UG/KG Exposure Time: (29D PREG) Result: Specific Developmental Abnormalities: Urogenital system. Specific Developmental Abnormalities: Hepatobiliary system. Effects on Embryo or Fetus: Fetotoxicity (except death, e.g., stunted fetus). Species: Rabbit Dose: 1 MG/KG Exposure Time: (20D PREG) Result: Effects on Embryo or Fetus: Fetal death. Species: Rabbit Dose: 204 UG/KG Exposure Time: (29D PREG) Result: Effects on Embryo or Fetus: Other effects to embryo. Dose: 2 MG/KG Route of Application: Intravenous Exposure Time: (8D PREG) Result: Specific Developmental Abnormalities: Craniofacial (including nose and tongue). Dose: 2 MG/KG Route of Application: Intravenous Exposure Time: (8D PREG) Result: Specific Developmental Abnormalities: Eye, ear. Specific Developmental Abnormalities: Central nervous system. Effects on Embryo or Fetus: Other effects to embryo. CHRONIC EXPOSURE - MUTAGEN Result: May alter genetic material. Species: Human Dose: 1 MMOL/L Cell Type: fibroblast Mutation test: DNA damage Species: Human Dose: 15 UMOL/L Cell Type: HeLa cell Mutation test: DNA inhibition Species: Human Dose: 50 UMOL/L Exposure Time: 24H Cell Type: lymphocyte Mutation test: Cytogenetic analysis Species: Human Dose: 1 UMOL/L Cell Type: leukocyte Mutation test: Cytogenetic analysis FLUKA Page 11

12 Species: Human Dose: 5 UMOL/L Cell Type: lymphocyte Mutation test: Sister chromatid exchange Species: Human Dose: 1 MG/L Cell Type: lymphocyte Mutation test: SLN Dose: 300 NMOL/L Cell Type: Other cell types Mutation test: Morphological transformation. Route: Intraperitoneal Dose: 10 MG/KG Exposure Time: 5D Mutation test: Unscheduled DNA synthesis Route: Subcutaneous Dose: 12 MG/KG Exposure Time: 3D Mutation test: Unscheduled DNA synthesis Route: Subcutaneous Dose: 12 MG/KG Exposure Time: 3D Mutation test: Other mutation test systems Route: Intraperitoneal Dose: 6 MG/KG Exposure Time: 3D Mutation test: DNA inhibition Dose: 10 NMOL/L Cell Type: Other cell types Mutation test: DNA inhibition Dose: 3500 NMOL/L Cell Type: Embryo Mutation test: Cytogenetic analysis Route: Subcutaneous Dose: 1824 UG/KG Mutation test: sperm Route: Intraperitoneal Dose: 50 UG/KG Mutation test: Micronucleus test Dose: 9 UMOL/L Cell Type: fibroblast FLUKA Page 12

13 Mutation test: Morphological transformation. Route: Inhalation Dose: 4900 UG/M3/1H-C Mutation test: Unscheduled DNA synthesis Route: Intraperitoneal Dose: 4 MG/KG Mutation test: DNA inhibition Dose: 10 UMOL/L Cell Type: Other cell types Mutation test: DNA inhibition Route: Subcutaneous Dose: 3 MG/KG Mutation test: Other mutation test systems Route: Subcutaneous Dose: 3 MG/KG Mutation test: Cytogenetic analysis Route: Intraperitoneal Dose: 420 UG/KG Mutation test: Cytogenetic analysis Route: Intraperitoneal Dose: 840 UG/KG Mutation test: Sister chromatid exchange Route: Intraperitoneal Dose: 10 UMOL/KG Mutation test: SLN Route: Intraperitoneal Dose: 2 MG/KG Mutation test: Dominant lethal test Route: Oral Dose: 15 MG/KG Mutation test: Dominant lethal test Dose: 140 UG/L Cell Type: lymphocyte Mutation test: Mutation in mammalian somatic cells. Dose: 6 MG/KG Cell Type: S. typhimurium Mutation test: Host-mediated assay FLUKA Page 13

14 Route: Intraperitoneal Dose: 1 MG/KG Mutation test: sperm Route: Subcutaneous Dose: UG/KG Mutation test: sperm Route: Unreported Dose: 1 MG/KG Mutation test: sperm Dose: 500 UG/L Cell Type: ovary Mutation test: Micronucleus test Dose: 625 UG/L Cell Type: lung Mutation test: Micronucleus test Dose: 2 UMOL/L Cell Type: Embryo Mutation test: Morphological transformation. Dose: 2 UMOL/L Cell Type: ovary Mutation test: DNA damage Dose: 20 UMOL/L Cell Type: lung Mutation test: DNA damage Dose: 10 UMOL/L Cell Type: Embryo Mutation test: Unscheduled DNA synthesis Dose: 10 UMOL/L Cell Type: lung Mutation test: DNA inhibition Dose: 500 UG/L Cell Type: ovary Mutation test: Other mutation test systems Dose: 1100 UG/L Cell Type: Embryo Mutation test: Other mutation test systems Dose: 250 UG/L FLUKA Page 14

15 Cell Type: ovary Mutation test: Cytogenetic analysis Dose: 1 UMOL/L Cell Type: lung Mutation test: Cytogenetic analysis Dose: 600 UG/L Cell Type: Embryo Mutation test: SLN Dose: 1 UMOL/L Cell Type: lung Mutation test: Mutation in mammalian somatic cells. Route: Subcutaneous Dose: 40 UMOL/KG Mutation test: sperm Species: Guinea pig Route: Subcutaneous Dose: 40 UMOL/KG Mutation test: sperm Species: Chicken Dose: 100 UMOL/L Cell Type: Other cell types Mutation test: DNA damage Species: Mammal Dose: 350 UMOL/L Cell Type: lymphocyte Mutation test: DNA damage Species: Mammal Dose: 2 UMOL/L Cell Type: kidney Mutation test: DNA inhibition Species: Rabbit Route: Subcutaneous Dose: 40 UMOL/KG Mutation test: sperm Species: other fish Route: Intraperitoneal Dose: 1000 PPM Mutation test: Micronucleus test CHRONIC EXPOSURE - REPRODUCTIVE HAZARD Result: Overexposure may cause reproductive disorder(s) based on tests with laboratory animals. Dose: 652 MG/KG Exposure Time: (7-16D PREG) Result: Effects on Fertility: Litter size (e.g.; # fetuses per FLUKA Page 15

16 litter; measured before birth). Maternal Effects: Ovaries, fallopian tubes. Effects on Fertility: Post-implantation mortality (e.g., dead and/or resorbed implants per total number of implants). Dose: 326 MG/KG Exposure Time: (1-20D PREG) Result: Effects on Fertility: Pre-implantation mortality (e.g., reduction in number of implants per female; total number of implants per corpora lutea). Effects on Embryo or Fetus: Fetotoxicity (except death, e.g., stunted fetus). Effects on Embryo or Fetus: Fetal death. Dose: 48 MG/KG Exposure Time: (90D PRE/1-22D PREG) Result: Effects on Newborn: Other postnatal measures or effects. Dose: 210 MG/KG Exposure Time: (1-21D PREG/21D POST) Result: Effects on Newborn: Other postnatal measures or effects. Effects on Newborn: Growth statistics (e.g., reduced weight gain). Dose: 55 MG/KG Exposure Time: (1-22D PREG) Result: Effects on Newborn: Biochemical and metabolic. Effects on Newborn: Live birth index (# fetuses per litter; measured after birth). Dose: 2 MG/KG Route of Application: Intraperitoneal Result: Paternal Effects: Testes, epididymis, sperm duct. Dose: 2 MG/KG Route of Application: Intraperitoneal Exposure Time: (10D PREG) Result: Effects on Embryo or Fetus: Fetotoxicity (except death, e.g., stunted fetus). Effects on Fertility: Post-implantation mortality (e.g., dead and/or resorbed implants per total number of implants). Dose: 1250 UG/KG Result: Paternal Effects: Spermatogenesis (including genetic material, sperm morphology,motility, and count). Paternal Effects: Testes, epididymis, sperm duct. Paternal Effects: Prostate, seminal vessicle, Cowper's gland, accessory glands. FLUKA Page 16

17 Dose: 2 MG/KG Route of Application: Intravenous Exposure Time: (8D PREG) Result: Specific Developmental Abnormalities: Musculoskeletal system. Effects on Fertility: Post-implantation mortality (e.g., dead and/or resorbed implants per total number of implants). Effects on Fertility: Litter size (e.g.; # fetuses per litter; measured before birth). Dose: 2 MG/KG Route of Application: Intravenous Exposure Time: (14D PREG) Result: Effects on Embryo or Fetus: Fetal death. Effects on Fertility: Post-implantation mortality (e.g., dead and/or resorbed implants per total number of implants). Dose: 4 MG/KG Route of Application: Intramuscular Result: Paternal Effects: Prostate, seminal vessicle, Cowper's gland, accessory glands. Dose: 2 MG/KG Route of Application: Intraperitoneal Exposure Time: (7D PREG) Result: Effects on Embryo or Fetus: Fetal death. Effects on Embryo or Fetus: Fetotoxicity (except death, e.g., stunted fetus). Effects on Fertility: Post-implantation mortality (e.g., dead and/or resorbed implants per total number of implants). Dose: 4 MG/KG Route of Application: Intraperitoneal Exposure Time: (10D PREG) Result: Specific Developmental Abnormalities: Musculoskeletal system. Effects on Fertility: Litter size (e.g.; # fetuses per litter; measured before birth). Effects on Fertility: Post-implantation mortality (e.g., dead and/or resorbed implants per total number of implants). Dose: 1 MG/KG Route of Application: Intraperitoneal Result: Effects on Fertility: Male fertility index (e.g., # males impregnating females per # males exposed to fertile nonpregnant females). Dose: 4 MG/KG Exposure Time: (7D PREG) Result: Effects on Embryo or Fetus: Extra embryonic structures (e.g., placenta, umbilical cord). Effects on Fertility: Post-implantation mortality (e.g., dead and/or resorbed implants per total number of implants). Effects on Embryo or Fetus: Fetotoxicity (except death, e.g., stunted fetus). FLUKA Page 17

18 Dose: 3 MG/KG Exposure Time: (1D PRE) Result: Maternal Effects: Oogenesis. Dose: 5700 UG/KG Exposure Time: (8-10D PREG) Result: Effects on Embryo or Fetus: Extra embryonic structures (e.g., placenta, umbilical cord). Effects on Fertility: Post-implantation mortality (e.g., dead and/or resorbed implants per total number of implants). Dose: 73 MG/KG Route of Application: Intravenous Result: Paternal Effects: Testes, epididymis, sperm duct. Species: Dog Dose: 7330 UG/KG Route of Application: Intratesticular Result: Paternal Effects: Testes, epididymis, sperm duct. Species: Monkey Dose: 12 MG/KG Result: Paternal Effects: Testes, epididymis, sperm duct. Paternal Effects: Prostate, seminal vessicle, Cowper's gland, accessory glands. Species: Rabbit Dose: 990 MG/KG Exposure Time: (1-6D PREG) Result: Effects on Fertility: Other measures of fertility Species: Rabbit Dose: 4583 NG/KG Result: Paternal Effects: Spermatogenesis (including genetic material, sperm morphology,motility, and count). Paternal Effects: Testes, epididymis, sperm duct. Species: Rabbit Dose: 2500 UG/KG Exposure Time: (1D PRE) Result: Effects on Fertility: Other measures of fertility Species: Rabbit Dose: 5 MG/KG Exposure Time: (1D PRE) Result: Effects on Fertility: Pre-implantation mortality (e.g., reduction in number of implants per female; total number of implants per corpora lutea). FLUKA Page 18

19 Species: Rabbit Dose: 1520 UG/KG Route of Application: Intratesticular Result: Paternal Effects: Prostate, seminal vessicle, Cowper's gland, accessory glands. Paternal Effects: Testes, epididymis, sperm duct. Effects on Fertility: Male fertility index (e.g., # males impregnating females per # males exposed to fertile nonpregnant females). Species: Guinea pig Dose: 2500 UG/KG Route of Application: Parenteral Exposure Time: (1D PRE) Result: Maternal Effects: Ovaries, fallopian tubes. Dose: 3666 UG/KG Route of Application: Intraperitoneal Result: Paternal Effects: Testes, epididymis, sperm duct. Dose: 5 MG/KG Exposure Time: (1D PRE) Result: Effects on Fertility: Other measures of fertility Effects on Fertility: Female fertility index (e.g., # females pregnant per # sperm positive females; # females pregnant per # females mated ). Dose: 8 MG/KG Result: Paternal Effects: Testes, epididymis, sperm duct. Species: Rabbit Dose: 2 MG/KG Route of Application: Intravenous Exposure Time: (8D PREG) Result: Effects on Embryo or Fetus: Fetotoxicity (except death, e.g., stunted fetus). Effects on Fertility: Post-implantation mortality (e.g., dead and/or resorbed implants per total number of implants). Specific Developmental Abnormalities: Craniofacial (including nose and tongue). Species: Gerbil Dose: 5600 UG/KG Result: Paternal Effects: Testes, epididymis, sperm duct. Paternal Effects: Prostate, seminal vessicle, Cowper's gland, accessory glands. Species: Squirrel Dose: 7332 MG/KG Result: Paternal Effects: Testes, epididymis, sperm duct. Paternal Effects: Prostate, seminal vessicle, Cowper's gland, accessory glands. FLUKA Page 19

20 Species: Mammal Dose: 7332 UG/KG Result: Paternal Effects: Testes, epididymis, sperm duct. Species: Mammal Dose: 2400 UG/KG Route of Application: Unreported Result: Paternal Effects: Testes, epididymis, sperm duct. Species: Mammal Dose: 500 UG/KG Route of Application: Intratesticular Result: Paternal Effects: Prostate, seminal vessicle, Cowper's gland, accessory glands. Paternal Effects: Testes, epididymis, sperm duct. Section 12 - Ecological Information No data available. Section 13 - Disposal Considerations APPROPRIATE METHOD OF DISPOSAL OF SUBSTANCE OR PREPARATION Contact a licensed professional waste disposal service to dispose of this material. Dissolve or mix the material with a combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber. Observe all federal, state, and local environmental regulations. Section 14 - Transport Information DOT Proper Shipping Name: Cadmium compounds UN#: 2570 Class: 6.1 Packing Group: Packing Group III Hazard Label: Toxic Substance PIH: Not PIH IATA Proper Shipping Name: Cadmium compound IATA UN Number: 2570 Hazard Class: 6.1 Packing Group: III Section 15 - Regulatory Information EU DIRECTIVES CLASSIFICATION Symbol of Danger: T+-N Indication of Danger: Very toxic. Dangerous for the environment. R: /23/25-50/53 Risk Statements: May cause cancer. May cause heritable genetic damage. May impair fertility. May cause harm to the unborn child. Also toxic if swallowed. Also very toxic by inhalation. Also toxic: danger of serious damage to health by prolonged exposure through inhalation and if swallowed. Very toxic to aquatic organisms, may cause long-term adverse effects in the FLUKA Page 20

21 aquatic environment. S: Safety Statements: Restricted to professional users. Attention - Avoid exposure - obtain special instructions before use. In case of accident or if you feel unwell, seek medical advice immediately (show the label where possible). This material and its container must be disposed of as hazardous waste. Avoid release to the environment. Refer to special instructions/safety data sheets. US CLASSIFICATION AND LABEL TEXT Indication of Danger: Highly Toxic (USA) Very Toxic (EU). Dangerous for the environment. Risk Statements: May cause cancer. May cause heritable genetic damage. May impair fertility. May cause harm to the unborn child. Also toxic if swallowed. Also very toxic by inhalation. Toxic: danger of serious damage to health by prolonged exposure through inhalation and if swallowed. Very toxic to aquatic organisms, may cause long-term adverse effects in the aquatic environment. Safety Statements: Restricted to professional users. Attention - Avoid exposure - obtain special instructions before use. In case of accident or if you feel unwell, seek medical advice immediately (show the label where possible). This material and its container must be disposed of as hazardous waste. Avoid release to the environment. Refer to special instructions/safety data sheets. US Statements: Danger: Contains cadmium. Cancer hazard. Avoid creating dust. Can cause lung and kidney disease. Calif. Prop. 65 carcinogen & developmental hazard. UNITED STATES REGULATORY INFORMATION SARA LISTED: Yes DEMINIMIS: 0.1 % NOTES: This product is subject to SARA section 313 reporting requirements - cadmium compounds. TSCA INVENTORY ITEM: Yes UNITED STATES - STATE REGULATORY INFORMATION CALIFORNIA PROP - 65 California Prop - 65: This product is or contains chemical(s) known to the state of California to cause cancer. This product is or contains chemical(s) known to the state of California to cause developmental toxicity. CANADA REGULATORY INFORMATION WHMIS Classification: This product has been classified in accordance with the hazard criteria of the CPR, and the MSDS contains all the information required by the CPR. DSL: Yes NDSL: No Section 16 - Other Information DISCLAIMER For R&D use only. Not for drug, household or other uses. WARRANTY The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a guide. The information in this document is based on the present state of our FLUKA Page 21

22 knowledge and is applicable to the product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the product. Sigma-Aldrich Inc., shall not be held liable for any damage resulting from handling or from contact with the above product. See reverse side of invoice or packing slip for additional terms and conditions of sale. Copyright 2008 Sigma-Aldrich Co. License granted to make unlimited paper copies for internal use only. FLUKA Page 22